文献速递眼底病与葡萄膜炎白内障与屈光手术

白内障术中玻璃体腔注射贝伐珠单抗与曲安奈德治疗糖尿病黄斑水肿的随机对照试验6个月结果

Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-month results.
PubMed 文献 · Br J Ophthalmol · 2019-02-28

这项前瞻性、双盲、单中心随机对照试验比较了白内障术中辅助玻璃体腔注射贝伐珠单抗(BVB)1.25 mg与曲安奈德(TA)4 mg对糖尿病黄斑水肿(DMO)患者的6个月疗效。共纳入58例患者61只眼,结果显示两组最佳矫正视力(BCVA)均显著提高且组间无显著差异,但TA组在6个月时中央黄斑厚度(CMT)较基线显著持续改善,而BVB组无此改善且组间差异显著。

要点

  • 白内障术中辅助TA或BVB均能显著改善DMO患者6个月视力,两组间无显著差异。
  • TA组6个月CMT较基线显著降低(-51.4 µm),BVB组无显著变化,组间差异显著(p=0.04)。
  • TA组多数患者术后无需进一步治疗,解剖学获益持续。

核心结论

  • 白内障术中辅助TA或BVB均能改善DMO患者6个月视力,但仅TA带来持续CMT改善。

研究设计与样本

  • 前瞻性、双盲、单中心(皇家维多利亚眼耳医院,墨尔本)随机对照试验,58例患者61只眼1:1随机接受BVB 1.25 mg或TA 4 mg术中注射。

主要发现

  • 6个月时TA组平均视力增益+21.4字母(95%CI +14.5至+28.4),BVB组+17.3字母(95%CI +12.1至+22.6),组间p=0.35。
  • TA组6个月CMT较基线降低-51.4 µm(95%CI -98.2至-4.7),BVB组增加+15.6 µm(95%CI -26.4至+57.7),组间p=0.04。

临床怎么用

  • 对于合并DMO的白内障手术患者,术中辅助TA可带来持续解剖改善并减少术后追加治疗需求。

局限性

  • 单中心设计可能限制结果外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To report the 6-month results of a clinical trial that compared intravitreous bevacizumab (BVB) 1.25 mg versus triamcinolone acetonide (TA) 4 mg when administered as an adjunct during cataract surgery to patients with diabetic macular oedema (DMO). METHODS: Prospective, double-masked, single-centre (Royal Victorian Eye and Ear Hospital, Melbourne) clinical trial. Patients with visually significant cataract and centre-involving DMO (either current or prior) were randomised (1: 1) to receive either intravitreous BVB 1.25 mg or TA 4 mg at the time of cataract surgery and if required at review. Main outcome measures were changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline to the 6-month time point of this 12-month study. RESULTS: 61 eyes of 58 patients were enrolled. At baseline, both groups were similar in terms of BCVA and CMT (p>0.2). At 6 months, there was no significant difference in vision between the groups, with mean letter gain of +21.4 (95% CI +14.5 to +28.4) in the TA group and +17.3 (95% CI +12.1 to +22.6) in the BVB group (p=0.35). The TA group had a significant sustained anatomical improvement at 6 months, with a reduction in CMT (-51.4 µm; 95% CI -98.2 to -4.7) compared with thickening in the BVB group (+15.6 µm; 95% CI -26.4 to +57.7, p=0.04). CONCLUSIONS: When given as an adjunct to cataract surgery, both TA and BVB improved visual outcomes at 6 months postoperatively. However, only TA resulted in sustained improvement in CMT, with the majority not requiring any further treatment postoperatively.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kandasamy R, Constantinou M, Rogers SL, et al. Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-month results. Br J Ophthalmol. 2019. PMID: 30819688. doi:10.1136/bjophthalmol-2018-313437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。